Valeant (VRX) Miss and Guide Down Expected, But Magnitude Maybe Not - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Reports Third Quarter 2016 Financial Results
November 8, 2016 6:00 AM EST- Total Revenues of $2.48 billion
- GAAP Cash Flow from Operations of $570 million
- GAAP EPS of ($3.49) and Adjusted EPS (non-GAAP) of $1.55
- Revising 2016 Full Year Guidance
LAVAL, Quebec, Nov. 8, 2016 /PRNewswire/ --Â Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced third quarter 2016 financial results.
"This past quarter, we made further progress toward establishing the new Valeant," said Joseph C. Papa, Chairman and Chief Executive Officer. "We have, where... More
